Skip to main content
. 2022 Jan 13;107(9):2108–2120. doi: 10.3324/haematol.2021.279012

Figure 3.

Figure 3.

Progression-free survival per investigator assessment according to IGHV mutation status. CI: confidence interval; mo: months; NE, not estimable; PFS, progression-free survival.